Curated News
By: NewsRamp Editorial Staff
August 06, 2026

Liquid Biopsy Predicts Immunotherapy Response in Lung Cancer

Discuss on LinkedIn Discuss on X, formerly Twitter Discuss on Substack Discuss on Telegram participate in discussion on bluesky Participate in discussion on Mastodon View History of this news story on GitHub
Original Source

TLDR

  • New liquid biopsy predicts immunotherapy response, giving firms like Calidi Biotherapeutics a strategic edge in clinical trials.
  • The liquid biopsy detects biomarkers in blood to forecast lung cancer patients' response to immunotherapy, improving treatment decisions.
  • This simple blood test helps more lung cancer patients receive effective immunotherapy, reducing futile treatments and personal suffering.
  • A drop of blood may soon tell doctors whether immunotherapy will work for advanced lung cancer, sparing patients from ineffective treatments.

Impact - Why it Matters

This news matters because it addresses a critical challenge in cancer treatment: predicting which patients will benefit from immunotherapy. By offering a simple blood test to forecast responses, this liquid biopsy could spare patients from ineffective treatments and their side effects, while also helping drug developers like Calidi Biotherapeutics optimize clinical trials. Ultimately, this could lead to more personalized and effective cancer care, improving survival rates and quality of life for lung cancer patients.

Summary

Immunotherapy has transformed cancer treatment, but its effectiveness varies widely among patients, with many not responding or developing resistance over time. To address this, researchers have developed a new liquid biopsy that offers a simpler method to predict which advanced lung cancer patients are likely to benefit from immunotherapy. This breakthrough, highlighted in a recent article, could significantly improve treatment decisions and patient outcomes.

The liquid biopsy, which analyzes blood samples, provides a non-invasive way to gauge a patient's potential response to immunotherapies. This is particularly valuable for companies like Calidi Biotherapeutics Inc. (NYSE American: CLDI), which are developing cutting-edge immunotherapies. By incorporating this predictive tool into clinical trials, these companies can better select patients who are most likely to respond, thereby increasing the efficiency and success rates of their studies. This advancement is part of a broader effort to personalize cancer care and optimize the use of immunotherapies.

BioMedWire, a specialized communications platform for the biotech and life sciences sectors, reported on this development. As part of the Dynamic Brand Portfolio at IBN, BioMedWire delivers news and insights to a wide audience, including investors and industry professionals. The platform's coverage of such innovations underscores its role in disseminating actionable information that can influence investment decisions and clinical practice.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Liquid Biopsy Predicts Immunotherapy Response in Lung Cancer

blockchain registration record for this content.